Want to see AURX full AI Analyst Report?
AURX Stock Chart & Stats
$1.07
$0.00(0.00%)
At close: 4:00 PM EST
$1.07
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.77 - $2.92
Previous CloseN/A
Volume8.36K
Average Volume (3M)5.26K
Market Cap
$62.96M
Enterprise Value$47.83M
Total Cash (Recent Filing)$449.32K
Total Debt (Recent Filing)$1.50M
Price to Earnings (P/E)―
Beta-0.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,433,777
10 Day Avg. Volume11,632
30 Day Avg. Volume5,263
Financial Highlights & Ratios
PEG Ratio-10.00
Price to Book (P/B)-97.44
Price to Sales (P/S)28.13
P/FCF Ratio-81.78
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue9.20
Enterprise Value/Gross Profit14.35
Enterprise Value/Ebitda-30.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginStrong top-line growth alongside a healthy gross margin indicates improving commercial traction and meaningful economics on sales. If maintained, this combination can support reinvestment in commercialization and gradually improve operating leverage as the company scales its wound-care business.
Focused Regenerative Medicine ProductThe company has a clearly defined therapeutic focus in regenerative medicine and wound care, centered on one core product and a specific chronic-wound application. This concentration can support focused commercialization, clinical positioning, and development of expertise in an identifiable medical niche.
Improving Loss And Cash-Burn TrendAlthough cash generation remains negative, improving free cash flow and less severe historical cash burn indicate progress in the operating trajectory. Continued improvement could reduce the pace of external funding required and provide a foundation for better financial resilience over the next several quarters.
Bears Say
Persistent UnprofitabilityThe company has not yet demonstrated sustained profitability, with materially negative operating and net margins despite improving results from earlier years. Persistent losses can constrain reinvestment, weaken financial flexibility, and make future growth dependent on continued access to outside capital.
Negative Equity And Rising DebtNegative equity and rising debt create a strained capital structure relative to ongoing losses. This reduces balance-sheet flexibility, increases reliance on external funding, and leaves the company less able to absorb operating setbacks or finance expansion without additional financing.
Costly Financing And Dilution RiskThe latest financing improves liquidity but adds a high 12% interest burden and warrants that can dilute existing shareholders. These terms raise the cost of capital and may limit the long-term benefit of funding if operating cash flow remains negative and additional financing is needed.
Nuo Therapeutics News
AURX FAQ
What was Nuo Therapeutics’s price range in the past 12 months?
Nuo Therapeutics lowest stock price was $0.77 and its highest was $2.92 in the past 12 months.
What is Nuo Therapeutics’s market cap?
Nuo Therapeutics’s market cap is $62.96M.
When is Nuo Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nuo Therapeutics’s earnings last quarter?
Currently, no data Available
Is Nuo Therapeutics overvalued?
According to Wall Street analysts Nuo Therapeutics’s price is currently Overvalued.
Does Nuo Therapeutics pay dividends?
Nuo Therapeutics does not currently pay dividends.
What is Nuo Therapeutics’s EPS estimate?
Nuo Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuo Therapeutics have?
Nuo Therapeutics has 48,433,777 shares outstanding.
What happened to Nuo Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nuo Therapeutics?
Currently, no hedge funds are holding shares in AURX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuo Therapeutics
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.